leisure time -WSS

leisure time

author：leisure time 2025-09-28 23:48:28 - browse：5523

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Malaysia cuts short music fest after British band slams anti

WSS

How a key Senate committee is planning to regulate PBMs

Special counsel alerts court to Trump’s social media post

Thousands protest mob assault of women who were paraded naked in remote Indian border state

Tuesday set an unofficial record for the hottest day on Earth. Wednesday may break it.

My chronic pain journey would have been easier knowing 5 things % STAT

Severe heat forecast: Where scorching temperatures will persist over the next week

explore

leisure time

hotspot

Sports medicine is finally prioritizing gender equality

Men with early prostate cancer can safely opt out of treatment

After affirmative action ruling, medical educators look to 'holistic review'

Pharma needs to include young adults in clinical research

New air purifier tech could be key to improving indoor air quality

4 missing after record

Walensky prepares to leave CDC — and Congress — behind

FDA approves first blood sugar monitor without finger pricks

Drug repurposing or repositioning? The language matters

Medical schools are missing the mark on artificial intelligence

focus

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

FDA approves first blood sugar monitor without finger pricks

Does Medicare's free annual wellness visit do any good?

Medical mystery: When an infection after surgery isn’t what it seems

Pediatricians' group reaffirms support for gender

explore

hotspot

explore

focus